Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 5/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30365594 | 0.93 | GABRA5 (0.41) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL25209850 | 0.83 | LMNA (0.45) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL25226928 | 0.82 | ATR (0.44) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL3456534 | 0.82 | EGLN2 (0.47) | ATRGSK3BDYRK1AIRAK4IGF1R | |
| SCHEMBL12403192 | 0.82 | GABRA5 (0.45) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL12125903 | 0.81 | TP53 (0.45) | ATRPTPN11 | |
| SCHEMBL25229723 | 0.80 | RAB9A (0.40) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL15051042 | 0.80 | L3MBTL1 (0.47) | AAK1 | |
| SCHEMBL13623044 | 0.80 | IRAK4 (0.42) | ATRGSK3BDYRK1AIRAK4IGF1R | |
| SCHEMBL10298873 | 0.80 | GABRA5 (0.46) | GABRA5GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565496-B2 | Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-03 | — | — | US | disclosed |
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4188928-B1 | SUBSTITUTED 1 H-PYRROLO[3,2-B]PYRIDIN COMPOUNDS AND METHODS OF USE THEREOF | BAYER AG (DE) | 2024-07-24 | — | — | EP | disclosed |
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| EP-4188928-A1 | SUBSTITUTED 1 H-PYRROLO[3,2-B]PYRIDIN COMPOUNDS AND METHODS OF USE THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-4188930-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | CYP11B2, SDHA, UGT2B7 | GABRA5 681/4885GABRA1 884/4885GABRG2 921/4885 |
| US-12565496-B2 | Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof | CYP1B1, CBR1, CYP4B1 | GABRA5 1691/4885GABRA1 741/4885GABRG2 979/4885 |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | CYP1B1, CYP4B1, CYP2C19 | GABRA5 906/4885GABRA1 619/4885GABRG2 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.